[ad_1]
The European Commission is not aware of any link between the European Medicines Agency (EMA) and the Chinese developer of the coronavirus vaccine, nor is the European Commission in contact with the developer of the Chinese vaccine, said Stefan De Keersmaecker, spokesman. of the European Commission.
He stressed that he was putting the European Union’s vaccination strategy on obtaining quality vaccines, vaccines that the European Medicines Agency (EMA) considered effective and safe.
All of this is very important to build the confidence of Europeans. The European Commission has assembled a wide and comprehensive portfolio of vaccines developed by all companies that meet the strict EU criteria.
The spokesperson pointed. The European Commission has so far identified AstraZeneca (400 million doses), Sanofi-GSK (300 million doses), Johnson & Johnson (400 million doses), BioNTech-Pfizer (600 million doses), CureVac (405 million doses) doses) and signed vaccine supply contracts with Moderna (160 million doses).
The European Medicines Agency is in preliminary negotiations with the manufacturer of the Russian coronavirus vaccine, Sputnik V. However, the Russian company has not yet decided to apply for approval in the EU.
European Commission President Ursula von der Leyen said on Friday that all vaccines marketed in the EU must be tested by the European Medicines Agency (EMA). Following an informal videoconference of EU health ministers on Wednesday, Stella Kiriakidis, EU Commissioner for Health and Food Safety, recalled that last June the 27 member states had authorized the European Commission to negotiate pre-vaccination orders in their Name:
By approving the agreement and transferring the negotiations to the Union, they all agreed not to initiate their own procedure for purchasing vaccines in the same laboratories.
Erik Mamer, chief spokesman for the European Commission, said in late November that vaccines available or to be available in the European Union must meet relevant EU approval and quality standards. However, in an emergency, Member States may derogate from this requirement on a temporary and limited basis in an emergency. In this case, they can also market products without the permission of the European Medicines Agency (EMA). However, in an emergency, vaccines provisionally authorized by Member States on their own responsibility may only be placed on the market in their own territory and not in another EU Member State.
Stefan De Keersmaecker, spokesperson for the board, emphasized:
The Member State applying the vaccine will be responsible for placing it on the market without authorization from the EU.
According to your information, if a vaccine is licensed by a Member State, the vaccine will be marketable in that Member State. The European Commission supports the authorization of vaccines used in the EU by the European Medicines Agency. The Agency carefully studies the efficacy and safety of vaccines before they are marketed. The procedure is very important to ensure the safety of European citizens, the spokesperson added.
[ad_2]
